Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alefacept
- Development stage
- Phase 4
- Lead developer
- Biogen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous
01
Overview
Alefacept is a recombinant dimeric fusion protein immunosuppressant used to treat moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It consists of the extracellular CD2-binding portion of human leukocyte function antigen-3 (LFA-3) linked to the Fc portion of human IgG1, produced via recombinant DNA technology in Chinese Hamster Ovary cells. Alefacept works by binding to CD2 on T lymphocytes, inhibiting their activation and proliferation through blockade of the LFA-3/CD2 interaction, and by inducing apoptosis in memory-effector T lymphocytes. This results in reduced numbers and activity of pathogenic T cells involved in psoriasis pathogenesis[1][3][4][5].
- Brand names
- Amevive
- Other names
- LFA-3/IgG1 fusion proteinLFA-3-IgLFA3-IgLFA 3-IgLFA3-FcLFA-3-FcLFA 3-Fc
02
Targets
CD2 (T-cell Surface Antigen CD2)
Beyond the preview
Go deeper on alefacept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alefacept.